StockNews.AI
CODX
StockNews.AI
109 days

Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

1. Co-Diagnostics will release Q1 2025 results on May 8. 2. Management will hold a conference call to discuss results. 3. The company focuses on molecular diagnostics technologies.

3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results may surpass expectations, similar to past quarters. A strong report could enhance investor confidence.

How important is it?

The article directly discusses upcoming earnings, crucial for market performance. Positive financial trends could significantly influence CODX's stock price.

Why Short Term?

Investors will react quickly to the Q1 results, impacting CODX stock immediately. Historical patterns show price movements often follow earnings announcements closely.

Related Companies

PCRNVTATMO
SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagnostics.com on the Events & Webcasts page, or accessible directly here Conference Call: 800-715-9871 (Toll Free) or (646) 307-1963 (Toll) with participant passcode 1977478 If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website. About Co-Diagnostics, Inc. Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease. Investor Relations Contact: Andrew BensonHead of Investor Relations+1 801-438-1036investors@codiagnostics.com

Related News